493
Downloads
12
Episodes
This is the monthly podcast of ACCRU, designed to tell the stories behind the innovative research of our members. Our mission is to establish the next level study for cancer research across the major disease groups. We promise our members the resources and collaboration to conduct innovative trials that transform patient care.ACCRU stands for ”Academic and Community Cancer Research United.”
Episodes
Friday Apr 01, 2022
Friday Apr 01, 2022
In this episode, podcast host Dr. Ciara O’Sullivan interviews Dr. Catherine Diefenbach about her innovative research for relapsed mantle cell lymphoma. Dr. Diefenbach is currently director of hematology translational research as well as director of the Clinical Lymphoma Program at NYU’s Langone Perlmutter Cancer Center. Dr. Diefenbach discusses a current ACCRU study that has the potential to prolong the survival of R/R MCL patients, including BTK inhibitor-resistant patients, or even have a role in the frontline treatment of elderly or unfit patients who are ineligible for aggressive chemo-immunotherapy.
Monday Mar 14, 2022
Immunologist Dr. Keith Knutson on the Promise of Cancer Vaccines
Monday Mar 14, 2022
Monday Mar 14, 2022
In our inaugural episode, Dr. Keith Knutson, an immunologist and professor of immunology at Mayo Clinic in Jacksonville, Florida, discusses the promise of vaccines for cancer recurrence. Dr. Knutson's research focus is on the immunology and immunotherapy of breast and ovarian cancers, both the basic immunobiology and clinical translation, including clinical trials. His work is aimed at preventing patients with these cancers from relapsing after receiving optimal conventional therapies. Dr. Knutson is the principal investigator of a vaccine study, open through ACCRU, that is testing a folate alpha receptor vaccine to stimulate the immune system of patients with TNBC who disease-free following conventional therapy. In addition, as it relates to HER2-positive breast cancer, Dr. Knutson and another colleague at Mayo Clinic, Dr. Saranya Chumsri, lead a phase II Trial to Evaluate Immune-related Biomarkers for Pathological Response in patients with Stage II-III HER2-postive Breast Cancer Receiving Neoadjuvant Chemotherapy.